Osmotic gradient ektacytometry: A valuable screening test for hereditary spherocytosis and other red blood cell membrane disorders

2017 ◽  
Vol 40 (1) ◽  
pp. 94-102 ◽  
Author(s):  
E. Llaudet-Planas ◽  
J. L. Vives-Corrons ◽  
V. Rizzuto ◽  
P. Gómez-Ramírez ◽  
J. Sevilla Navarro ◽  
...  
Blood ◽  
1995 ◽  
Vol 85 (3) ◽  
pp. 634-640 ◽  
Author(s):  
P Jarolim ◽  
HL Rubin ◽  
V Brabec ◽  
L Chrobak ◽  
AS Zolotarev ◽  
...  

To elucidate the molecular basis of band 3 deficiency in a recently defined subset of patients with autosomal dominant hereditary spherocytosis (HS), we screened band 3 cDNA for single-strand conformation polymorphism (SSCP). In 5 of 17 (29%) unrelated HS subjects with band 3 deficiency, we detected substitutions R760W, R760Q, R808C, and R870W that were all coinherited with the HS phenotype. The involved arginines are highly conserved throughout evolution. To examine whether or not the product of the mutant allele is inserted into the membrane, we studied one HS subject who was doubly heterozygous for the R760Q mutation and the K56E (band 3sMEMPHIS) polymorphism that results in altered electrophoretic mobility of the band 3 Memphis proteolytic fragments. We detected only the band 3MEMPHIS in the erythrocyte membrane indicating that the protein product of the mutant, R760Q, band 3 allele is absent from the red blood cell membrane. These findings suggest that the R760Q substitution, and probably the other arginine subsitutions, produce band 3 deficiency either by precluding incorporation of the mutant protein into the red blood cell membrane or by leading to loss of mutant protein from differentiating erythroid precursors.


2005 ◽  
Vol 74 (5) ◽  
pp. 396-401 ◽  
Author(s):  
Paulo Roberto Moura Lima ◽  
Mariana Ozello Baratti ◽  
Maria Lucia Chiattone ◽  
Fernando Ferreira Costa ◽  
Sara Teresinha Olalla Saad

Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 99
Author(s):  
Xinyi Wu ◽  
Yichen Li ◽  
Faisal Raza ◽  
Xuerui Wang ◽  
Shulei Zhang ◽  
...  

Multiple drug resistance (MDR) in bacterial infections is developed with the abuse of antibiotics, posing a severe threat to global health. Tedizolid phosphate (TR-701) is an efficient prodrug of tedizolid (TR-700) against gram-positive bacteria, including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). Herein, a novel drug delivery system: Red blood cell membrane (RBCM) coated TR-701-loaded polylactic acid-glycolic acid copolymer (PLGA) nanoparticles (RBCM-PLGA-TR-701NPs, RPTR-701Ns) was proposed. The RPTR-701Ns possessed a double-layer core-shell structure with 192.50 ± 5.85 nm in size, an average encapsulation efficiency of 36.63% and a 48 h-sustained release in vitro. Superior bio-compatibility was confirmed with red blood cells (RBCs) and HEK 293 cells. Due to the RBCM coating, RPTR-701Ns on one hand significantly reduced phagocytosis by RAW 264.7 cells as compared to PTR-701Ns, showing an immune escape effect. On the other hand, RPTR-701Ns had an advanced exotoxins neutralization ability, which helped reduce the damage of MRSA exotoxins to RBCs by 17.13%. Furthermore, excellent in vivo bacteria elimination and promoted wound healing were observed of RPTR-701Ns with a MRSA-infected mice model without causing toxicity. In summary, the novel delivery system provides a synergistic antibacterial treatment of both sustained release and bacterial toxins absorption, facilitating the incorporation of TR-701 into modern nanotechnology.


2001 ◽  
Vol 81 (1) ◽  
pp. 43-56 ◽  
Author(s):  
Guillaume Lenormand ◽  
Sylvie Hénon ◽  
Alain Richert ◽  
Jacqueline Siméon ◽  
François Gallet

Sign in / Sign up

Export Citation Format

Share Document